eBook: adapting to an evolving drug modality landscape
Over the past decade, the pharmaceutical industry has witnessed a notable evolution in drug development modalities. Advancements in technology have equipped pharmaceutical companies to efficiently introduce biologics like peptide and protein therapeutics, alongside synthetic oligonucleotides. Simultaneously, traditional small molecules have endured as a mainstay.
In this eBook, we explore how bioanalytical laboratories, involved from early to late-stage discovery and clinical trials, must remain adaptable to evolving analytical challenges posed by ever-expanding drug modalities.
Contents include:
- INTERVIEW: 60 seconds with Alderley Analytical’s CEO, Paul Holme: navigating the dynamic evolution of bioanalysis
- RESEARCH ARTICLE: Investigation of the pharmacokinetics and metabolic fate of Fasiglifam (TAK-875) in male and female rats following oral and intravenous administration
- APPLICATION NOTE: An automated, standardized, kit-based sample preparation workflow for bioanalytical quantification of therapeutic oligonucleotides
- RESEARCH ARTICLE: Assessing the impact of nonspecific binding on oligonucleotide bioanalysis
- RESEARCH ARTICLE: Rapid determination of the pharmacokinetics and metabolic fate of gefitinib in the mouse using a combination of UPLC/MS/MS, UPLC/QToF/MS, and ion mobility (IM)-enabled UPLC/QToF/MS
- APPLICATION NOTE: Rapid high sensitivity LC−MS/MS bioanalytical method for the simultaneous quantification of Gefitinib based PROTACs – 3 and Gefitinib in rat plasma to support discovery DMPK studies
In association with
